The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial | SCAI

In the United States, the Watchman Device (Boston Scientific, Marlborough, MA) is approved for implantation accompanied by 45 days of anticoagulation with warfarin. ASAP TOO is a prospective randomized trial comparing the Watchman device accompanied by 90 days of aspirin and clopidogrel dual antiplatelet therapy to no Watchman device. The trial is enrolling 888 subjects who are too high risk to take even 45 days of warfarin at 99 global centers. Randomization is 2:1 Watchman vs. control. This on-going trial began enrollment in February 2017.

All Editors: Andrew M. Goldsweig, MD, MCS, RPVI, FSCAI

Integrated Search Topics